# Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

> **NCT05243017** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **UniQure Biopharma B.V.** · enrollment: 14 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **GENETIC:** intra-striatal rAAV5-miHTT

## Key facts

- **NCT ID:** NCT05243017
- **Lead sponsor:** UniQure Biopharma B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-07
- **Primary completion:** 2029-03
- **Final completion:** 2029-10-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243017, "Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05243017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*